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A premenstrual screening tool is needed when time constraints and attrition limit the feasibility 
of daily ratings. The present study examines the utility of a novel, 33-item, retrospective, 
dimensional, DSM-5-based, screening measure developed to explore women’s perceptions of 
premenstrual symptomatology. This is the first measure that examines perception of impairment 
for each DSM-5 symptom and assesses the frequency criterion. Participants (N = 331) reported 
symptoms ranging from none to a level consistent with a provisional DSM-5 diagnosis of 
Premenstrual Dysphoric Disorder (PMDD). Initial psychometric properties indicated a five-
factor structure: (1) affective symptoms; (2) fatigue, sleep, and anhedonia; (3) symptom 
frequency; (4) impairment and severity of appetite change and physical symptoms; and (5) 
difficulty concentrating. The total symptom scale and the frequency, severity, and impairment 
subscales demonstrated high internal consistency. Strong correlations between this dimensional 
measure and other retrospective and prospective premenstrual symptom measures suggest strong 
convergent, concurrent, and predictive validity. Premenstrual symptom groups created using this 
screening measure (minimal, mild/moderate, severe) differed on other retrospective and 
prospective measures of premenstrual symptoms. There was evidence of divergent validity and 
lack of an acquiescence bias. We also report data describing women’s perceptions of the 
frequency, level of impairment, and level of severity for each DSM-5 PMDD symptom over a 
12-month period and discuss implications for future research on premenstrual phenomenology. 
Initial evidence for the reliability and construct validity of this symptom screening measure 
suggests potential value for assessing premenstrual symptomatology in research and practice. 
 Keywords: premenstrual symptoms, Premenstrual Syndrome, PMDD, screening, 
psychometrics
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Psychometric Properties of a DSM-5-Based Screening Tool for Women's Perceptions of 
Premenstrual Symptoms 
Premenstrual syndrome (PMS) is characterized by the cyclical aggregation of physical, 
cognitive, and emotional symptoms that occur in the late luteal (premenstrual) phase of the 
menstrual cycle and remit or abate in the week post-menses. When such symptoms occur in most 
menstrual cycles; are associated with clinically significant distress or interference with work, 
school, usual social activities or relationships with others; and cannot be ascribed to another 
disorder, a DSM-5 diagnosis of Premenstrual Dysphoric Disorder (PMDD) is warranted 
(American Psychiatric Association (APA), 2013). While up to 80% of reproductive-aged women 
report experiencing some premenstrual symptoms, 30% to 40% of women report PMS symptoms 
that require treatment, and 3% to 8% of women report symptoms meeting criteria for PMDD 
(Ryu & Kim, 2015). Across several studies, prevalence rates between 10% and 35% have been 
reported for severe PMS (e.g., subthreshold PMDD) (Halbreich et al., 2003; Hylan et al.,1999; 
Johnson, 2004; Wittchen et al., 2002), with 20.3% of women in one study reporting missing at 
least one work day during the year due the experience of PMS symptoms (Robinson & Swindle, 
2000). While valid prospective rating scales for assessing PMS and PMDD have been developed 
(Eisenlohr-Moul et al., 2017), there are practical constraints that prohibit many women from 
completing the required two months of prospective daily symptom monitoring. Further, the 
symptom frequency diagnostic criteria cannot be addressed with a prospective measure. There 
remains a need for the development of an accessible DSM-5-based retrospective screening tool 
to measure women’s experience of premenstrual symptoms in both research and practice.    
The heterogeneity of tools for the assessment of PMS and PMDD includes measures that 
are both prospective (i.e., following/assessing current experiences over time) and retrospective 
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(i.e., assessment of past/current experiences), with a formal diagnosis requiring prospective 
charting for two consecutive cycles (Steiner et al., 2003).   The most prevalent retrospective 
measures used to assess for the presence of PMS and/or PMDD include: The Menstrual Distress 
Questionnaire (MDQ) (Moos, 1968), which has been reported as one of the most well-cited 
questionnaires developed for the assessment of PMS symptoms (Haywood et al., 2002); the 
Premenstrual Assessment Form (PAF) (Halbreich et al., 1982); and the Premenstrual Symptoms 
Screening Tool (PSST) (Steiner et al., 2003). Prospective rating scales for the assessment of 
PMS symptoms include: the Daily Symptom Rating Scale (DSRS) (Taylor, 1979), the Calendar 
of Premenstrual Events (COPE) (Mortola et al., 1990), the Cyclicity Diagnoser Scale (CD) 
(Sundström et al., 1999), and the Daily Record of Severity of Problems (DRSP) (Endicott et al., 
2006). None of these measures, however, align with the most recent criteria for PMDD as 
outlined in the DSM-5, potentially limiting the extent to which these criteria and women’s 
experiences with the symptoms described within them can be investigated. 
The current “gold-standard” for the measurement of PMS symptoms and PMDD is the 
Carolina Premenstrual Assessment Scoring System (C-PASS) (Eisenlohr-Moul et al., 2017). The 
C-PASS is a standardized scoring algorithm for making dimensional and categorical PMDD 
diagnoses using two or more months of daily DSRP symptom ratings. The scoring algorithm 
allows for the establishment of a categorical diagnosis (yes/no PMDD) and several dimensional 
measures of PMDD, including (1) Dimensional Cyclicity, (2) Dimensional Severity, and (3) 
Dimensional Frequency/Duration. A total score, individual symptom score, and impairment 
score as it relates to work, relationships, and/or hobbies can also be calculated for each 
dimensional index.  The C-PASS is thus a robust measure that allows for prospective symptom 
tracking and the assessment of individual symptoms as dimensions.  
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The requirement of prospective reporting over two consecutive menstrual cycles is 
considered a diagnostic necessity for evaluating the presence of PMDD given research 
suggesting a historical lack of agreement between retrospective and prospective assessments of 
premenstrual symptoms (Rubinow et al., 1984; Eisenlohr-Moul et al., 2017). High levels of both 
PMS symptoms and PMS-related functional impairments have also been observed in a cross 
section of women completing retrospective reports compared to those who completed both 
prospective and retrospective reports (Cohen et al. 2002).  Although retrospective and 
prospective ratings of affective PMS/PMDD symptoms are usually positively correlated, 
previous studies suggest that many women misdiagnose their chronic psychiatric symptoms as 
PMS (Rubinow & Roy-Byrne, 1984).  
We are in agreement that prospective ratings are essential in establishing a diagnosis of 
PMDD but recognize that this gold standard is often not practical or feasible. For women in any 
of the following contexts, the reliable completion of two months of daily prospective ratings may 
be difficult or minimally possible: (1) women who suffer from symptoms that are significantly 
impairing, (2) women with extremely severe symptoms, (3) women with cognitive or executive 
dysfunction, and/or (4) women who are overwhelmingly or disproportionality affected by social 
or occupational demands that constrain time. Completion of prospective daily ratings is time 
consuming and requires intentionality, which may prevent certain women from committing to it. 
For example, Cohen et al. (2002) reported that 47% of a sample of 976 women screened into a 
study and asked to complete prospective daily ratings did not agree to do so. As well, the C-
PASS validation study reported an attrition rate of 25% after women were invited to complete 
prospective daily ratings (Eisenlohr-Moul et al., 2017). Thus, while two months of prospective 
daily ratings are essential to maintaining diagnostic fidelity, it is likely that this practice limits 
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both research and practice. In research, important information relating to the constructs of PMS 
and PMDD is lost to attrition when women are unable to complete the ratings. In practice, some 
women may not receive a PMDD diagnosis or treatment due to the difficulty of the diagnostic 
requirements.  
Despite studies citing a lack of agreement between retrospective and prospective 
premenstrual symptom ratings, we submit that a validated brief screening tool based on DSM-5 
criteria is beneficial for three primary reasons. First, such a tool will identify potential women 
who might qualify for a provisional diagnosis of PMDD and would be good candidates to 
complete the more labor intensive two-month prospective rating process (with support if 
needed).  Second, a retrospective measure is the only way to examine the DSM-5 criterion 
requiring that symptoms be present “for most menstrual cycles that occurred in the preceding 
year” (APA, 2013, p. 172). Third, the screening tool will help further research into the 
investigation of women’s symptoms and their perceptions of the effect(s) that these symptoms 
have on their day-to-day functioning. From a psychological perspective, the explication of 
women’s retrospective perceptions of their premenstrual symptoms and their effects can help us 
better understand the psychosocial evolution of these beliefs and their internalization by both 
individuals and, possibly, a wider culture. Clinically, this understanding can help tailor 
interventions targeting perceived premenstrual symptom impairment or interference in 
functioning regardless of whether women meet the diagnostic threshold for PMDD or their 
premenstrual symptoms exacerbate an underlying disorder such as depression (e.g., PME). This 
is an important consideration for psychological interventions as psychiatric disorders including 
major depressive disorder, anxiety disorders, and personality disorders have been reported as co-
occurring frequently with PMS and PMDD (Hartlage & Gehlert, 2001). An increased 
DSM-5-BASED SCREENING FOR PREMENSTRUAL SYMPTOMS   
 
7
understanding of women’s perceptions of premenstrual symptom type, symptom frequency, and 
symptom impairment can aid in the development of therapeutic tasks for women seeking 
treatment for premenstrual-related distress. 
Here we propose a new short (e.g., under five minutes) retrospective measure of 
premenstrual symptoms based upon DSM-5 diagnostic criteria. We also examine the construct 
validity (i.e., convergent, criterion, and discriminant validity) of the proposed dimensional 
measure. For each DSM-5 PMDD symptom, we report retrospective data for a 12-month period 
which highlights women’s perceptions of symptom frequency, degree of impairment, and 
severity. To our knowledge, this is the first study that reports women’s perceptions of 
impairment in functioning for each premenstrual/PMDD symptom. With the exception of one 
item for which the wording was changed for ease of readability (see measure in the Appendix), 
the remaining items on this premenstrual symptom screening measure replicate the wording in 
DSM-5 criteria.  
The assessment tool was developed to screen for premenstrual symptoms and provisional 
PMDD in response to the American Psychiatric Association’s call for researchers to further 
investigate alternative items, thresholds, or durations associated with PMDD (APA, 2000). This 
new measure is in keeping with the dimensional model of mental illness adopted by the DSM-5 
and is capable of measuring premenstrual symptoms along a continuum of severity ranging from 
an absence of symptoms at one end to the provisional identification of women with PMDD at the 
other. An advantage of taking a dimensional approach to the measurement of PMS symptoms is 
that it allows for further explication of subclinical symptoms potentially experienced by large 
numbers of women and could therefore facilitate an increased scientific and psychosocial 
understanding of a collective phenomenological experience. 
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 The purpose of the present study was fourfold: 1) to present a retrospective dimensional 
screening tool for measuring premenstrual symptoms, 2) to provide preliminary psychometric 
data (e.g., reliability and construct validity data) on its utility as a clinical and research tool, 3) to 
evaluate the capacity of a dimensional screening tool to provide support for the validity of 
women’s reported experience of premenstrual symptoms as defined by the DSM-5, and 4) to 
present data reflective of women’s 12-month retrospective perception of symptom frequency and 
symptom impairment. The general construct validity of the proposed dimensional measure was 
assessed using principal components analysis (PCA). Additional analyses explored criterion 
(concurrent and predictive) validity, convergent validity, and discriminant validity. The 
following four predictions were made. (1) The new premenstrual measure will show strong 
positive correlations with the total premenstrual MDQ scale scores (convergent and concurrent 
criterion validity). (2) Symptom impairment groups created with the new measure will differ in 
MDQ premenstrual symptom scores (concurrent criterion validity). (3) Scores on the new tool 
will correlate positively with prospective lab measures of premenstrual pain, water retention, and 
negative affect (predictive criterion validity). (4) The new measure will show low or negative 
correlations with the control subscale of the MDQ, a subscale measuring non-cyclical symptoms 
(discriminant validity). Unlike previous retrospective measures, the proposed dimensional 
screening tool uses DSM-5 criteria and evaluates level of impairment for each individual DSM-5 
PMDD symptom, rather than using one impairment rating for all symptoms. These impairment 
ratings may provide useful information regarding which symptoms present the greatest challenge 
for women’s functioning in their day-to-day lives.  
 
 





 Women were recruited from a primarily undergraduate Canadian university as part of a 
larger study investigating women’s health and the influence of estradiol on visual system 
functioning.  This study was conducted in two phases. Phase one involved the completion of a 
large screening questionnaire on women’s health and reproductive functioning and phase two 
involved selecting a subset of women to participate in two laboratory sessions. Participants 
received bonus points in undergraduate psychology courses (phase 1 and 2) and a ten-dollar gift 
card (phase 2). The project was approved by the institutional research ethics board and informed 
consent was obtained from all participants. 
Three-hundred and thirty-one women (mean age = 20.61 years, SD = 4.60 years) 
completed the screening questionnaire in phase 1. Of these, 14.5% (N = 48) self-reported a 
history of diagnosis or treatment for depression and 12.4% (N = 41) reported such history for an 
anxiety disorder. All women were included in the analyses given that the presence of underlying 
mental health conditions does not preclude a diagnosis of either PMS or PMDD and underlying 
hormonal changes could predispose women to both premenstrual symptoms and mood disorders 
(Hartlage & Gehlert, 2001). 
A subsample of 29 women who were not pregnant or taking any form of hormonal 
contraceptives participated in the prospective symptom laboratory sessions (phase 2) of the study 
(mean age = 22.03, SD = 5.2). Of those women, half (N = 15) had retrospective MDQ scores for 
the premenstrual phase equal to or below the phase 1 sample median, and half (N = 14) scored 
above the phase 1 sample median.  
Measures 
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Background Questionnaire (BQ) 
The background questionnaire (BQ) was completed in phase 1 and included questions 
regarding: demographics (age and education), medical and mental health history, premenstrual 
symptoms, and reproductive history. Reproductive history was assessed with questions regarding 
age of menarche, parity, typical length of menstrual cycle, length of menses, time of last 
menstrual period, and cycle regularity. PMS symptoms were assessed using a 33-item 
dimensional screening measure of PMS symptom severity based on DSM-5 symptoms and the 
Menstrual Distress Questionnaire (MDQ) (Moos, 1968).  
Screening Measure of Premenstrual Symptoms. A 33-item scale using the DSM-5 
criteria for PMDD (APA, 2013) in a new format was used to screen for premenstrual symptom 
severity, frequency, and impairment. See the Appendix for the items and the question format.  
These items/criteria were established based on expert opinions and their analysis of available 
data in the area of premenstrual disorders and PMDD (Epperson et al., 2012). For each of the 
eleven sets of PMDD symptoms listed in the DSM-5, participants are asked three questions 
assessing: (1) the severity with which the symptoms are experienced; (2) the degree to which the 
symptoms impair work, school, or interpersonal performance or functioning; and (3) the 
frequency with which the symptoms were experienced over the past year. Questions assessing 
impairment and severity were rated using five-point likert scales anchored by 0 (not at all) on 
one end, and 4 (extremely) for impairment; and 0 (not at all) and 4 (extremely 
severe/debilitating) for severity. Frequency question response options ranged from 0 to 12 
months, indicating how many menstrual cycles a particular symptom is experienced over a one-
year period. From these scores, four premenstrual symptom scores can be calculated: frequency, 
severity, impairment, and total score. As described below, premenstrual symptom impairment 
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and severity groups were created based on these scores such that women were assigned to one of 
three symptom groups corresponding to: 0 (minimal; scores of 0 to 11), 1 (mild/moderate; scores 
ranging from 11 to 22), or 2 (severe; scores > 22). 
Menstrual Distress Questionnaire (MDQ). The MDQ (Moos, 1968) consists of 47 
items, each of which is rated on a five-point scale corresponding to 0 (no experience of the 
symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong)  and 4 (present, severe) 
with respect to either current experiences (e.g., today) (MDQ – Form T) or experiences during 
three phases (menstrual, intermenstrual, premenstrual) of the most recent menstrual cycle (MDQ 
– Form C). The MDQ consists of eight scales derived from empirically distinct, although 
correlated, sets of symptoms: pain, concentration, water retention, behavior change, negative 
affect, autonomic reactions, arousal, and control.  Of these scales, Moos (1968) reports that all 
except for arousal and control show large differences between premenstrual and intermenstrual 
phase scores. Examination of the factor structure of the MDQ provides evidence for the construct 
validity of all eight scales as effectively representing the structure of menstrual cycle symptoms 
(Ross et al., 2003). As well, exploratory factor analysis and LISREL analyses support the 
reliability and validity of the MDQ (Boyle, 1992). The MDQ – Form C was used in the 
Background Questionnaire.   
Laboratory Questionnaire (LQ)  
In phase 2, participants completed a brief laboratory questionnaire designed to assess 
their current affective state and level of cycle-related discomfort during two lab sessions. The 
four scales (noted below) were completed prospectively within the two laboratory sessions that 
were scheduled in a counterbalanced manner in both the late follicular (LF) and the premenstrual 
(PM) menstrual cycle phases and were used as prospective measures of premenstrual symptoms.  
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Positive and Negative Affect Scale (PANAS). The PANAS (Watson et al., 1988) 
consists of two 10-item scales for positive affect (PA) and negative affect (NA). Scale reliability 
is unaffected by the time period specified in the instructions and alphas range from .86 to .90 for 
PA and from .84 to .87 for NA (Watson et al., 1988). Convergent and divergent validity evidence 
comes from correlations with measures of anxiety, depression, and stress (Crawford & Henry, 
2004). In the present study, both the PA and the NA scales were used as part of the prospective 
measurement of emotional premenstrual symptoms at two different lab sessions. NA is a general 
dimension reflecting subjective distress and unpleasant mood states, including anger, contempt, 
and disgust; while PA is a general dimension reflecting energy, concentration, and meaningful 
engagement. The NA scale includes items such as: distressed, upset, and irritable; and the PA 
scale includes items such as interested, excited and enthusiastic. Participants were asked to 
indicate how they felt at the moment they were completing the surveys in each lab session. They 
were asked to rate each adjective on a five-point response scale corresponding to 1 (very slightly 
or not at all), 2 (a little), 3 (moderately), 4 (quite a bit), and 5 (extremely).  
Menstrual Distress Questionnaire – Form T (MDQ-T). To prospectively assess 
menstrual cycle related pain and/or discomfort, two scales from the MDQ-T (see above) were 
included in the Laboratory Questionnaire to examine current experiences (e.g., today) (i.e., the 
pain and water retention scales). The scales were used as prospective measures of premenstrual 
symptomatology to examine the initial predictive criterion validity of the new PMS symptom 
screening measure. Markham (1976) reported that the MDQ-T is internally consistent with 
alphas ranging from .82 to .98. 
 
 





Participants were recruited for phase 1 of a study examining “visual functioning in 
women”, which involved completing the Background Questionnaire online. All retrospective 
premenstrual symptom measures were collected at the beginning of the Background 
Questionnaire (i.e., immediately after the demographic questions), with the Screening Measure 
of Premenstrual Symptoms following the MDQ. Completion of these measures at the beginning 
of the questionnaire should minimize any carry-over effects from subsequent measures. 
Phase 2  
Participants were selected to participate in two laboratory sessions corresponding to two 
phases of the menstrual cycle when reproductive hormones differ; the LF phase when estradiol is 
increasing just before ovulation and the PM phase, when estradiol is decreasing. These sessions 
were scheduled as described below. The first task in each lab session involved completing the 
Laboratory Questionnaire which included four prospective measures of mood and premenstrual 
symptoms (i.e., PANAS PA and NA scales; and the MDQ-T pain and water retention scales). 
Completion of these measures at the start of the sessions reduced the possibility of any carry-
over effects from the psychophysical tests completed later (for the larger study).  
Scheduling of Laboratory Sessions 
The mean laboratory testing days were days 14.48 (SD = 1.96) for the LF session and 
25.03 (SD = 1.38) for the PM session (forward count). To ensure that women attended the 
laboratory during the appropriate menstrual cycle phases (i.e., late follicular and premenstrual 
phases), an initial meeting was set up prior to data collection in which participants provided their 
menstrual cycle dates using calendars and self-report information. This information was 
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supplemented by the provision of ovulation test strips. These strips are sensitive to the pre-
ovulatory surge in luteinizing hormone (LH) and change color when the presence of the hormone 
is detected in urine. They were used to corroborate the timing of laboratory sessions in the LF 
phase of the menstrual cycle, when levels of estradiol are rising or high. Participants were 
instructed on the use of these strips and the interpretation of the results.   
  Sessions for the PM phase were scheduled in the initial orientation meeting based upon 
women’s current position in the menstrual cycle and the estimate of their typical cycle length. If 
the timing of the orientation meeting corresponded to the latter half of a woman’s menstrual 
cycle, she was scheduled for a first laboratory session in the PM phase based upon her cycle-
length estimate. Women were subsequently asked to contact the researchers upon the start of 
their next menstrual period, at which point they were instructed to begin using the ovulation test 
strips in the post-menstrual week to schedule a second laboratory session following a positive 
result. The scheduling of laboratory sessions was counterbalanced. Confirmation of next 
menstruation allowed cycle day at the time of laboratory testing to be established using the 
backwards count method. These days corresponded to -10 to -20 for the LF phase and -1 to -8 for 
the PM phase. 
Premenstrual Symptom Groups 
Scores on the PMS symptom screening measure were considered in combination with 
DSM-5 criteria for PMDD (APA, 2013) to categorize the severity of PMS symptoms (minimal, 
mild/moderate, and severe), PMS impairment level (minimal, mild/moderate, and severe), and to 
provide a provisional diagnosis of PMDD (yes, no). Women’s responses on the PMS symptom 
screener were coded, as described below, based on whether they satisfied PMDD (provisional) 
criteria A through D in the DSM-5.  
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Criterion A (APA, 2013) reflects symptom frequency and was established in three steps. 
First, each of the 11 PMDD symptom sets were recoded as “1” if a woman experienced them in 
seven or more menstrual cycles (i.e., more menstrual cycles than not), and “0” if experienced in 
six or fewer menstrual cycles in a one-year period. Second, these 11 new dichotomous symptom 
frequency variables were summed (possible range of 0 to 11). Third, women whose scores were 
five or higher, reflecting the experience of five or more symptoms in more menstrual cycles than 
not in a one-year period, met the threshold for criterion A. 
Meeting criteria B and C for DSM-5 PMDD (APA, 2013) requires that one of four 
symptom sets be present from cluster B (items 1 to 4), one of seven symptom sets be present 
from cluster C (items 5 to 11), and that five symptom sets be present across the two clusters (see 
the Appendix). The requirement that there be five symptoms across the two clusters was already 
examined within criteria A. To establish the presence of criteria B and C, the 11 dummy 
variables created to examine criteria A for the 11 PMS symptoms (e.g., symptoms occurring in 
seven or more menstrual cycles) were used. Women were classified as meeting criteria B and C 
if they endorsed at least one symptom set from each of these two separate symptom groups and 
the cumulative total symptom sets across clusters B and C was five or greater.  
Criterion D was established in two different ways using women’s ratings for both (a) 
impairment and (b) severity. Thus, for the purpose of the present study, women were said to 
meet Criterion D if they met cutoffs for either impairment or severity. For both impairment and 
severity, women were assigned to one of three groups to reflect level of premenstrual symptom 
severity or impairment: 0 (minimal), 1 (mild/moderate), or 2 (severe). The range of scores 
corresponding to each of these categories was determined by considering the maximal score a 
woman would receive if she were to endorse all symptoms as being equally problematic. For 
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example, endorsing each of the 11 symptoms with a rating of 0 or 1, corresponding to a 
negligible or mild level of impairment or severity, would result in a score between 0 and 11. 
Scores within this range were therefore classified as minimal and subsumed a group of women 
who did not meet criteria for PMDD. This group included women who: (a) did not endorse 
symptoms as leading to impairment or as being severe, and (b) did not meet criteria A, B, or C 
but who may have had a score for impairment or severity exceeding 11. Women were classified 
as experiencing mild to moderate PMDD if they scored between 12 and 22, which required 
rating (at minimum) all symptoms with a value of mild and at least one symptom with a rating of 
moderate in terms of impairment or severity. Finally, women were classified as experiencing 
severe PMDD if their scores for either impairment or severity exceeded 23, which would require 
endorsing at least all 11 symptoms as moderate and one as severe. Thus, women whose scores 
were greater than 11 were considered to have met criterion D. Using scores for both impairment 
and severity, premenstrual symptom classification groups were based on the following scores: 1 
to 11 (minimal), 12 to 22 (mild/moderate), and 23 to 44 (severe).  
Results 
Principle Component Analyses 
To determine the underlying dimensions of our screening tool for provisional PMDD and 
PMS symptoms, an exploratory factor analysis (EFA) was first performed on the 33-items of the 
PMS symptom screening measure. Horn’s Parallel Analysis is a procedure recommended to 
determine the number of factors to extract (Tabachnick & Fidell, 2014), and was used as 
described by O’Connor (2000). Parallel analysis suggested the retention of five factors. The 
principal components analysis (PCA) using oblique (oblimin) rotation indicated that the five 
factors accounted for 66.11% of the variance. Oblique rotation was selected given the high 
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potential for factors within our model (e.g., assessment tool) to correlate. The Kaiser-Meyer-
Olkin measure verified the sampling adequacy for the analysis, KMO = .90, and all KMO values 
for individual items were > .81, which is above the acceptable limit of .5 (Field, 2009). Bartlett’s 
test of sphericity χ2 (528) = 9851.13, p < .001, indicated that correlations between items were 
sufficiently large for PCA. 
Table 1 shows the factor loadings for the primary five components after rotation, 
including eigenvalues, variance, and reliability (e.g., Cronbach’s a). The items that cluster on 
these components suggest that component one represents affective symptoms and accounts for 
41.80% of the variance; component two is reflective of sleep disruption, fatigue, and decreased 
interest, and accounts for 8.02% of the variance; component three represents frequency for five 
symptoms and accounts for 6.81% of the variance; component four represents impairment and 
severity of appetite change and physical symptoms and accounts for 5.08% of the variance; and 
component five represents difficulty concentrating and accounts for 4.40% of the variance. 
Cronbach’s alpha for the five components ranged from .62 to .85. 
Reliability and Internal Consistency of the Overall Scale and Subscales 
 Three exploratory PCAs with oblique rotation were then performed for each of the 11-
item frequency, impairment, and severity scales. A summary of these analyses as well as means, 
SDs, and internal consistency values are found in Table 2. These analyses indicated that each 
scale is principally comprised of one component accounting for between 47.98% and 49.74% of 
the variance, with internal consistencies ranging from .89 to .90. The overall PMS symptom 
screening measure (all 33 items) also had high internal consistency, with an overall Cronbach 
alpha coefficient of .92.  
Convergent and Criterion Validity (Concurrent and Predictive)  
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Convergent validity for the retrospective PMS symptom screener was evaluated by 
correlating the total item score and individual frequency, impairment, and severity scale scores 
with the retrospective premenstrual phase MDQ total score and individual scale scores. The 
MDQ total score was calculated using seven of the eight MDQ scales, omitting the arousal scale, 
as the items within this scale are not consistent with the experience of premenstrual symptoms 
(e.g., well-being) as outlined in the DSM-5. For example, (Boyle, 1992) reported that the MDQ 
arousal scale contains items associated with positive reactions across the menstrual cycle and 
that the scale did not correlate significantly with any other factors derived from the MDQ. The 
results are presented in the top section of Table 3. The correlations are high, supporting the 
convergent validity for the PMS symptom screening measure. The correlation between the 
screening measure’s total score and the overall MDQ premenstrual phase score was r = .70, p < 
.001, providing evidence of  convergent validity for the screening tool.  
The three individual subscale scores and the total score of the PMS symptom screening 
tool were all positively correlated with prospective lab measures of pain, water retention, and NA 
during the premenstrual phase (see bottom portion of Table 3). The correlations were generally 
above .50, with total scores best predicting premenstrual phase PANAS NA scores, r = .70, p < 
.001. These correlations support the predictive criterion validity of the new screening tool. 
Additionally, with the exception of PA, the individual scales of the PMS symptom screening tool 
were all positively associated with the prospective lab change scores, which were calculated by 
subtracting prospective late-follicular phase scores from premenstrual phase scores. These 
correlations were strongest for NA and suggest that women with more premenstrual NA 
symptoms relative to symptoms during the late-follicular phase, have higher scores on the PMS 
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symptom screening measure. These correlations provide support for the predictive criterion 
validity of the PMS symptom screening measure.  
To further examine the concurrent and predictive criterion validity of the dimensional 
PMS symptom measure, the symptom impairment classification groups were compared on the 
other retrospective and prospective premenstrual phase symptom scores (see Table 4). As results 
were similar for the symptom severity classification groups, these are not presented here (see 
Supplementary Table 1). These groups represent increasing levels of PMS symptomatology: 0 
(minimal), 1 (mild/moderate), and 2 (severe). 
 Two three-group MANOVAs using Pillai’s trace examined whether the three impairment 
groups created with the PMS symptom screening tool differ in PMS symptoms using the 
following dependent variables: (1) retrospective premenstrual phase MDQ data from the total 
sample of women, and (2) prospective laboratory data from the subsample of women in the 
premenstrual phase of their menstrual cycle. Given unequal variance between group means, the 
Games-Howell statistic was used for post-hoc analyses. The first MANOVA found that women’s 
scores on the seven retrospective MDQ scales during the premenstrual phase differed as a 
function of the impairment groups, V = .55, F(14, 636) = 17.41, p ≤ .001, h2 = .28. Follow-up 
univariate ANOVAs revealed significant differences between the impairment groups on each 
MDQ scale in the predicted directions (all p ≤ .001; see top of Table 4). It is noteworthy that the 
largest effect sizes were for the behavior change, impaired concentration, and negative affect 
MDQ scales, suggesting that the impairment group categories are strongly associated with 
differences in behavior, concentration, and mood. The second MANOVA indicated that the 
impairment groups differed on prospective premenstrual phase symptoms reported in the lab 
session, V = .79, F(6, 50) = 5.05, p  ≤ .001, h2 = .38. Follow-up univariate ANOVAs revealed 
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significant differences between the impairment groups on all prospective measures of 
premenstrual symptoms (all p ≤ .004) with the means indicating that the severe premenstrual 
symptom impairment group endorsed the highest level of prospective symptom expression for all 
variables, and the minimal group endorsed the lowest level of symptom expression for all 
variables (see bottom portion of Table 4). The largest effect size was found for the PANAS NA 
scale suggesting that the premenstrual symptom impairment groups are strongly differentiated in 
terms of negative emotional symptoms.  
 For both MANOVAs, Bartlett’s Test of Sphericity and Box’s Test of Equality of 
Covariances were significant. Thus, the non-parametric Kruskal-Wallis Test was used as a check 
to compare means for prospective and retrospective DVs as a function of group. With the 
exception of group means for prospective MDQ pain (p = .08), which was a non-significant trend 
for both impairment and severity groups, Kruskal-Wallis tests comparing means between groups 
across all prospective and retrospective DVs were all significant (all p < .001 for retrospective 
ratings and p < .05 for prospective ratings). These analyses suggest that the PMS symptom 
screening tool categorizes women into valid groups that differ in premenstrual symptoms as 
measured by prospective and other retrospective instruments. 
 To further examine whether impairment and severity grouping scores (0, 1, 2) from the 
new PMS symptom screening measure could be predicted using retrospective premenstrual 
symptom ratings (i.e., MDQ scale scores) and prospective premenstrual rating scores (i.e., two 
MDQ scales and the PANAS NA scale), four multiple regressions were performed. As in the 
above MANOVAs, separate regressions were completed on retrospective and prospective 
premenstrual scores for impairment grouping scores and severity grouping scores. A forced entry 
model was employed in which all retrospective or prospective premenstrual symptom predictors 
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of grouping scores were entered into the model simultaneously. For each of these analyses, the 
Durban-Watson statistic was selected as a test of the assumption of independent error as per 
Field (2009) and was returned within acceptable limits (range 1.83 to 2.12).  
A summary of the two regressions predicting impairment grouping scores is found in 
Table 5. For the impairment groups, the seven retrospective MDQ scale scores predicted group 
membership scores, F (7, 325) = 31.91 p <.001, adjusted R2 = .40. The four unique predictors of 
symptom impairment grouping scores were the NA (p < .001), impaired concentration (p = .01), 
behavior change (p  < .001), and control (p  = .005) scales. Higher impairment grouping scores 
were associated with higher scores on the NA (β = .28), impaired concentration (β = .20), and 
behavior change (β = .32) scales; and lower scores on the MDQ control scale (β = - .18). Given 
Moos’ (1968) addition of the control scale as a means of identifying women who endorse high 
levels of symptoms that are not typically associated with the menstrual cycle, the inverse 
relationship between the MDQ control scales and impairment group scores provides evidence of 
divergent/discriminant validity for the new premenstrual symptom screener and for the 
impairment groups.  
The second regression using the three prospective symptom measures collected during 
the premenstrual phase of the cycle (N = 29) as predictors of symptom impairment level was also 
significant, F(3, 28) = 16.22  p <.001, adjusted R2 = .62. These three prospective premenstrual 
measures explained 62% of the variance in the impairment grouping scores, which was higher 
than the 40% explained by the seven retrospective premenstrual symptom measures. Two of the 
prospective measures were unique predictors of PMS symptom impairment: MDQ water 
retention (p = .01) and PANAS NA (p = .002). Being screened into a higher symptom 
impairment group was associated with higher water retention and NA scores (see Table 5).  
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Given that the regression results were very similar for the symptom severity groups, a summary 
of the two regressions is provided in Supplementary Table 2. 
Discriminant Validity  
 Some preliminary evidence for the discriminant validity of the new PMS symptom 
screening measure comes from two findings. First, the regression coefficients (e.g., Bs) were 
negative and significant for the retrospective MDQ control scale scores in the prediction of group 
membership for both PMS symptom impairment and PMS symptom severity (see Table 5 and 
Supplementary Table 2). This suggests that women who score higher on our dimensional PMS 
symptom screening tool score lower on the MDQ control scale. Second, correlations between the 
individual scales of our PMS symptom screening dimensional tool and prospective change in PA 
were not significant, suggesting that scores on our PMS symptom screening tool are not 
associated with cyclical change in PA (see Table 3).  
To further evaluate the discriminant validity of the PMS symptom screening tool, three 
partial correlations were performed between retrospective MDQ control scores and each of: 1) 
overall scores on the PMS symptom screener, 2) the PMS screener impairment grouping scores, 
and 3) the PMS screener severity grouping scores; while controlling for scores on the other six 
retrospective MDQ scales. There were negative relationships between MDQ control scores and: 
overall scores on the PMS symptom screening measure (partial r = -.19, p < .001), impairment 
grouping scores (partial r = - .16, p  = .005), and severity grouping scores (partial r = - .21, p  < 
.001). The MDQ control scale contains items that are not typically associated with the experience 
of PMS or PMDD. The finding of an inverse association after statistically controlling for 
responses to the theoretically relevant symptom scales can be regarded as a potential check 
against acquiescence or over-endorsing response styles. This finding suggests that women who 
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endorse more symptoms on the new PMS symptom screening measure do not over-endorse all 
symptoms and that women with more PMS symptoms are, in fact, less likely than others to 
endorse control symptoms.  
Frequency, Severity, and Impairment of Premenstrual Symptoms 
 Given the above preliminary evidence of the reliability and construct validity of this 
screening tool, we used it to examine women’s experience of premenstrual symptom frequency, 
severity, and impairment. Means and standard deviations for women’s perceptions of the 
frequency, degree of impairment, and level of severity for each of the eleven symptoms of DSM-
5 premenstrual dysphoric disorder over a retrospective 12-month period are reported in Table 6. 
These results suggest that, over a retrospective one-year period, women perceive that they 
experience the physical symptoms with the highest mean frequency [7.91 months (SD = 4.44)], 
degree of impairment, and severity. Correlations between severity ratings and impairment ratings 
for each symptom are high and significant, (see Table 7), suggesting that for all symptoms, 
measurement of both severity and impairment may be redundant.   
Paired t-tests were used to compare mean symptom ratings to determine which symptoms 
women perceived as being highest and lowest in frequency, severity, and impairment, on 
average, and which symptom means differed (p < .05). In terms of symptom frequency (number 
of months in the past year), women reported the following symptoms as occurring most to least 
frequently on average: (1) physical symptoms, (2) appetite change, (3) fatigue = sleep changes = 
affective lability, (4) anger/irritability, (5) depressed mood = anxiety, (6) decreased interest = 
feeling overwhelmed, and (7) decreased concentration. With respect to symptom impairment, 
women reported the following symptoms as being most to least impairing on average: (1) fatigue 
= physical symptoms, (2) physical symptoms = sleep changes, (3) affective lability = 
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anger/irritability, (4) anger/irritability = decreased interest = depressed mood = anxiety = appetite 
change, and (5) appetite change = feeling overwhelmed = decreased concentration. Finally, for 
symptom severity, the symptoms that were reported as being most to least severe on average 
were: (1) physical symptoms, (2) appetite changes = sleep changes = fatigue = affective lability, 
(3) affective lability = anger/irritability, (4) depressed mood = anxiety = feeling overwhelmed, 
(5) feeling overwhelmed = decreased interest, and (6) decreased concentration. 
 Table 8 presents the percentage of women reporting each level of impairment for each 
DSM-5 PMDD symptom. The symptoms that women most frequently reported as causing some 
level of impairment were physical symptoms (67%), fatigue and lack of energy (64%), and sleep 
problems (59%). However, some impairment related to each of the emotional symptoms (Criteria 
B) was reported by about half of the women surveyed (46% to 54%). The symptom that was 
least likely to be reported as causing impairment was concentration difficulties, with 41% of 
women reporting at least some impairment. The symptoms that appeared to result in the highest 
levels of impairment were fatigue and lack of energy with the following levels of impairment 
noted: 18.5% moderate impairment, 10.6% quite a bit of impairment, and 4.6% extreme 
impairment. Supplementary Table 3 provides the same information for women’s ratings of PMS 
symptom severity. 
Discussion 
The purpose of the present study was fourfold: (1) to present a retrospective dimensional 
screening tool for measuring premenstrual symptoms; (2) to provide preliminary psychometric 
data (e.g. reliability and construct validity data) on its utility as a clinical and research tool for 
studying premenstrual symptoms and PMDD; (3) to evaluate the capacity of this dimensional 
screening tool to provide support for the validity of women’s reported experience of DSM-5 
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premenstrual symptoms; and (4) to use this tool to report women’s perceptions as they pertain to 
the frequency, impairment, and severity of the 11 DSM-5 PMDD symptoms over a 12-month 
retrospective period. This study lends support to the dimensionality of PMS phenomenology as a 
whole and, to our knowledge, is the first to report women’s retrospective perceptions of their 
experience with each DSM-5 premenstrual symptom, especially as they relate to frequency and 
impairment.  
A 5-Factor Structure with Internal Consistency and Convergent Validity  
The retrospective dimensional screening tool for DSM-5 PMS symptoms is presented in 
the Appendix. Factor analysis of this new dimensional measure indicates that items converge 
around five primary clusters reflecting: 1) affective symptoms, 2) sleep disruption, fatigue, and 
anhedonia, 3) symptom frequency, 4) impairment and severity of appetite and physical 
symptoms, and 5) concentration difficulties. PCAs of the frequency, impairment, and severity 
subscales indicate that each subscale is comprised of one primary internally consistent factor. 
Overall, the entire 33-item measure shows excellent internal consistency. 
Correlations between total and individual scale scores of the new PMS symptom 
screening measure and total and individual scale scores of the retrospective MDQ for items rated 
during the premenstrual phase suggest that the constructs assessed by these measures are 
strongly related. Individual correlations between each of the three, dimensional scales and the 
seven MDQ scales were generally large and highly significant (p £ .01) indicating good 
convergent validity between the two measures and supporting the capacity of dimensional 
measurement of the DSM-5 symptoms to capture the essence of premenstrual phenomenology.  
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Evidence of Predictive and Concurrent Criterion Validity 
Additional support for predictive criterion validity of the PMS symptom screening 
measure was determined using two methods. First, correlations between scores on the PMS 
symptom screening measure and prospective premenstrual MDQ pain, MDQ water retention, 
and PANAS NA scale scores (and change scores) collected during two sessions in the lab were 
highly significant and positive. This suggested good agreement between the new PMS symptom 
screening measure and prospective symptoms during the premenstrual phase of the menstrual 
cycle when PMS symptoms should be highest and provides initial evidence for predictive 
validity.  
Second, PMS symptom impairment and PMS symptom severity groups created with the 
new PMS symptom screening measure (i.e., minimal, mild/moderate, and severe) differed with  
both retrospective PMS symptom reports and prospective PMS symptom reports, providing 
evidence for criterion (both concurrent and predictive) validity. Women who were grouped 
according to their degree of PMS symptom impairment and PMS symptom severity on the 
screening measure differed significantly in (1) all seven retrospective MDQ scales supporting the 
dimensional measure’s concurrent validity and (2) their prospective premenstrual phase scores 
on two MDQ scales and the PANAS NA scale, supporting the measure’s predictive validity. 
That is, groups of women with higher PMS symptom impairment and higher PMS symptom 
severity scored higher on both prospective and retrospective PMS measures.  
Multiple regression analyses revealed that, together, retrospective MDQ scale scores 
explained 41.3% of variance in the PMS screener symptom impairment groupings. Retrospective 
scores on the MDQ NA, impaired concentration, behavior change, and control scales were 
unique predictors. The strongest unique effects were for behavior change, NA, and impaired 
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concentration, suggesting that the premenstrual symptom groups created using the new PMS 
symptom screening measure maximally capture group differences in these areas of functioning. 
Interestingly, pain was not a unique predictor.  
Impairment groups created with the PMS symptom screening measure were even more 
strongly predicted by prospective measures of symptoms. Together, scores on the three 
prospective premenstrual phase measures (pain, water retention, and NA scales) predicted 66.1% 
of the variance in the groupings for PMS symptom impairment. NA and water retention, but not 
pain, were unique predictors of group membership for PMS symptom impairment, suggesting 
that the new PMS symptom screening measure explains variance in emotional symptoms and 
water retention that are distinct from pain. This is not surprising given the focus on emotional 
symptoms in the DSM-5 criteria (APA, 2013). Support for the construct validity (i.e., concurrent 
and predictive criterion validity) of both the dimensionality of PMS symptoms and the grouping 
criteria of the new measure comes from the fact that group membership based upon increasing 
levels of impairment and severity using the dimensional tool was predicted using prospective and 
retrospective MDQ and PANAS data .  
Evidence of Discriminant Validity 
The finding that the retrospective MDQ control scale was negatively and significantly 
related to prediction of group membership in the regressions and partial correlations indicates 
that women who endorse more symptoms on the control scale have lower scores on the PMS 
symptom screening tool. This finding suggests that women endorsing higher levels of PMS 
symptoms within DSM-5 criteria, are actually less likely to endorse other symptoms that are not 
commonly reported to be a part of PMS or PMDD. The MDQ Control scale is populated with 
items that are not consistent with the experience of PMS but rather, are more consistent with the 
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experience of other, non-descript, neurological symptoms (e.g., ringing in the ears, heart 
pounding, and blind spots or fuzzy vision). The negative relationship between women’s scores 
on this new PMS symptom screening tool and MDQ control suggests that: (a) women who score 
high on the new dimensional measure do not do so because they adopt an acquiescent response 
style (e.g., a bias towards endorsing all items) when asked to report their experience of PMS 
symptoms; and (b) women who report a high level of PMS symptomatology are not simply 
women who tend to complain about everything, or are necessarily high in somatization. The 
finding lends validity to the overall phenomenology of premenstrual symptoms and premenstrual 
dysphoria, and provides evidence for the discriminant validity of the PMS symptom screening 
measure as an assessment tool capable of capturing women’s experience of PMS 
symptomatology. The finding also provides discriminant validity evidence for the DSM-5 
symptom set as a measure of premenstrual symptoms and PMDD. 
Women’s Experiences of Symptom Frequency, Severity, and Impairment 
Given preliminary evidence supporting the reliability and construct validity of this 
dimensional measure, data reflecting women’s perceptions of the frequency, impairment and 
severity of each DSM-5 PMDD symptom were examined. Regarding women’s perception of 
impairment, these data indicate that for each of the eleven DSM-5 PMDD symptoms, between 
16% and 33% of women report experiencing a moderate degree of impairment or higher during 
at least one menstrual cycle over a twelve-month retrospective period. Furthermore, the low and 
high ends of this range are anchored by: (a) subjective difficulty in concentration and (b) 
lethargy, easy fatigability, or marked lack of energy, respectively. Across symptoms, a high 
percentage of women also endorse a level of impairment of moderate or greater for physical 
symptoms (32.1%) and sleep disruption (30.3%). In terms of comparing women’s experience of 
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the frequency, severity, and impairment of the 11 DSM-5 symptoms; physical symptoms and 
decreased concentration stand out as the symptoms reported as the highest and lowest on 
average, respectively, in terms of frequency, severity, and impairment. However, separately 
measuring the various physical symptoms might lead to different findings. 
Notwithstanding the importance of diagnosing PMDD, which is necessary in seeking 
appropriate treatments and studying its underlying biological mechanisms, it is important to 
consider the manifestation of women’s perceptions of premenstrual symptoms to increase our 
psychosocial understanding of the construct of PMS and its effect on women’s phenomenology. 
Our data suggest that a high number of women perceive that they are impaired by a number of 
symptoms associated with a regularly occurring cyclical event. The implication of this perceived 
burden warrants further investigation to improve our understanding of women’s experiences and 
overall health care.  
Strengths and Limitations 
While the new PMS symptom screening tool yielded favourable psychometric properties, 
there are a few limitations to the present study. First, to diagnose PMDD, the DSM-5 stipulates 
in Criterion F that the temporal occurrence and frequency of symptoms (Criterion A) requires 
confirmation using prospective daily ratings over two or more cycles, which was not done here. 
Instead, prospective ratings on the PANAS and MDQ during the LF and PM phases of the 
menstrual cycle were used as metrics to show change across the menstrual cycle and to validate 
retrospective ratings. One noteworthy strength of these prospective ratings is that they were both 
performed in the lab under consistent controlled conditions at a specified date and time, which 
enhances their validity beyond at-home rating conditions. Future studies using this instrument 
should use two cycles of daily ratings to examine the ability of this measure to predict PMDD 
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diagnoses and PMS symptoms with that timeframe. Nevertheless, we submit that the preliminary 
psychometric properties of this new PMS symptom screening tool suggest that it could be useful 
in research and to clinically screen for women likely to meet the criteria for PMDD. There may 
be value in adapting the present scale to an alternative format that could also be used 
prospectively to evaluate the presence of PMDD symptoms in subsequent studies. Considering 
the study limitations, future research using this measure should examine test-retest reliability and 
focus on additional validation studies using a greater variety of women followed over a greater 
number of menstrual cycles. This would help provide additional evidence of predictive validity 
and discriminant validity.  
Second, with the exception of item nine on our measure, which was adapted to read 
sleeping too much or too little rather than “hypersomnia or insomnia” the remainder of the items 
were derived from the DSM-5 and the face validity or content validity of these items for a 
population of university aged women is unclear. Future iterations of this instrument should take 
into account the literacy level and interpretability of item content for use by different populations 
of women. It is worthwhile noting, however, that the scales for our PMS symptom screening tool 
correlate well with the MDQ scales (Table 3), which has historically been widely used and 
validated, suggesting that at minimum, women were able to infer the content of the items as they 
pertain to the menstrual cycle. Future studies should also counterbalance the presentation order 
of the PMS symptom screening tool with any other PMS measure, as that was not done here.  
The proposed PMS symptom screening tool has several advantages. It is based on current 
DSM-5 criteria and is capable of distinguishing women who meet screening criteria for DSM-5 
Premenstrual Dysphoric Disorder from the majority of women who experience premenstrual 
symptoms as non-clinical experiences. Given that the tool is designed to take dimensionality into 
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account, it would be useful in research settings for those investigating premenstrual symptoms 
alone or their interactions with other variables of interest. Moreover, given their high internal 
consistency and content validity, individual scales (i.e., symptom frequency, impairment, or 
severity) could be employed as standalone measures. 
Conclusion 
The present study provides preliminary evidence that the proposed screening measure for 
premenstrual symptoms is a psychometrically sound instrument that: (a) assesses the continuum 
of premenstrual symptoms from none/mild to severe using either impairment or severity ratings 
and (b) screens for a provisional diagnosis of PMDD using the most recently published DSM 
criteria. The retrospective data yielded by this measure shows excellent potential for advancing 
the study of women’s premenstrual symptom experience. In particular, this instrument suggests 
that there is benefit in studying women’s perceptions of impairments in functioning associated 
with premenstrual disorders, how these impairments translate to their day-to-day experiences 
(e.g., the functional domains in which women experience the most impairment), and how 
information from women’s ratings of individual symptoms could be used to tailor clinical 
interventions for their unique symptom presentation
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Some women experience changes in mood and physical functioning during the week prior to their menstrual period. As best as you can, please 
indicate the severity, level of impairment, and frequency of the following 11 symptoms during your PREMENSTRUAL PHASE over the past year. 
 
Symptoms* 
Please rate the degree of severity of these symptoms: 
 
To what extent do these symptoms cause impairment 
in work, school, or relationships with others?  
 Number of menstrual cycles in which 
the symptom(s) have been experienced 
























1. Marked affective 
lability (e.g., mood 
swings, feeling suddenly 
sad or tearful, or 
increased sensitivity to 
rejection). 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
2. Marked irritability or 
anger or increased 
interpersonal conflicts. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
3. Marked depressed 
mood, feelings of 
hopelessness or self-
deprecating thoughts. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
4. Marked anxiety, 
tension, and/or feelings 
of being keyed up or on 
edge. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
5. Decreased interest in 
usual activities (e.g. 
work, school, friends, 
hobbies). 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
6. Subjective difficulty 
in concentration. 0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
7. Lethargy, easy 
fatigability, or marked 
lack of energy. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
8. Marked change in 
appetite; overeating; or 
specific food cravings. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
9. Hypersomnia or 
insomnia. 0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
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10. A sense of being 
overwhelmed or out of 
control. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
11. Physical 
symptoms such as breast 
tenderness or swelling, 
joint or muscle pain, a 
sensation of “bloating” 
or weight gain. 
0 1 2 3 4 0 1 2 3 4 0  1  2  3  4  5  6  7  8  9  10  11  12 
The symptoms in column one are from the criteria for Premenstrual Dysphoric Disorder (PMDD) as they appear in the Diagnostic and Statistical Manual of Mental Disorders (5th 
Edition; DSM-5), (p. 171-172) by the American Psychiatric Association (APA), 2013, Arlington VA; APA. Reprinted with permission from the Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition, (Copyright ©2013). American Psychiatric Association. All Rights Reserved.  
 
*Note that item nine was adapted for a lower reading level in our assessment tool and reads as “Sleeping too much or too little.”  
 
 
